235 related articles for article (PubMed ID: 15982898)
1. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.
van Laarhoven HW; Punt CJ; Kamm YJ; Heerschap A
Crit Rev Oncol Hematol; 2005 Dec; 56(3):321-43. PubMed ID: 15982898
[TBL] [Abstract][Full Text] [Related]
2. Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs.
Malet-Martino M; Gilard V; Desmoulin F; Martino R
Clin Chim Acta; 2006 Apr; 366(1-2):61-73. PubMed ID: 16337167
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance spectroscopy applied to clinical oncology.
Leach MO
Technol Health Care; 1994 Dec; 2(4):235-46. PubMed ID: 7842308
[TBL] [Abstract][Full Text] [Related]
4. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
[TBL] [Abstract][Full Text] [Related]
5. [Application of multinuclear in vivo magnetic resonance spectroscopy in oncology].
Semmler W; Gückel F; Bachert-Baumann P; Lorenz WJ; van Kaick G
Radiologe; 1989 Jul; 29(7):330-5. PubMed ID: 2667032
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo.
Lemaire LP; McSheehy PM; Griffiths JR
Cancer Chemother Pharmacol; 1998; 42(3):201-9. PubMed ID: 9685055
[TBL] [Abstract][Full Text] [Related]
7. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours.
McSheehy PM; Port RE; Rodrigues LM; Robinson SP; Stubbs M; van der Borns K; Peters GJ; Judson IR; Leach MO; Griffiths JR
Cancer Chemother Pharmacol; 2005 Feb; 55(2):117-28. PubMed ID: 15592719
[TBL] [Abstract][Full Text] [Related]
8. Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver.
Klomp D; van Laarhoven H; Scheenen T; Kamm Y; Heerschap A
NMR Biomed; 2007 Aug; 20(5):485-92. PubMed ID: 17131325
[TBL] [Abstract][Full Text] [Related]
9. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs.
Martino R; Malet-Martino M; Gilard V
Curr Drug Metab; 2000 Nov; 1(3):271-303. PubMed ID: 11465049
[TBL] [Abstract][Full Text] [Related]
10. Interest of fluorine-19 nuclear magnetic resonance spectroscopy in the detection, identification and quantification of metabolites of anticancer and antifungal fluoropyrimidine drugs in human biofluids.
Martino R; Gilard V; Desmoulin F; Malet-Martino M
Chemotherapy; 2006; 52(5):215-9. PubMed ID: 16864998
[TBL] [Abstract][Full Text] [Related]
11. Application of NMR spectroscopy in biochemical studies of tumor cells sensitive and resistant to anticancer drugs.
Hanusovská E; Dovinová I; Tkác I; Novotný L
Neoplasma; 1998; 45(4):187-97. PubMed ID: 9890660
[TBL] [Abstract][Full Text] [Related]
12. New techniques in the pharmacokinetic analysis of cancer drugs. III. Nuclear magnetic resonance.
Maxwell RJ
Cancer Surv; 1993; 17():415-23. PubMed ID: 8137351
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole.
Schneider E; Bolo NR; Frederick B; Wilkinson S; Hirashima F; Nassar L; Lyoo IK; Koch P; Jones S; Hwang J; Sung Y; Villafuerte RA; Maier G; Hsu R; Hashoian R; Renshaw PF
J Clin Pharm Ther; 2006 Jun; 31(3):261-73. PubMed ID: 16789992
[TBL] [Abstract][Full Text] [Related]
14. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors.
Procissi D; Claus F; Burgman P; Koziorowski J; Chapman JD; Thakur SB; Matei C; Ling CC; Koutcher JA
Clin Cancer Res; 2007 Jun; 13(12):3738-47. PubMed ID: 17575240
[TBL] [Abstract][Full Text] [Related]
15. Fluorine magnetic resonance in vivo: a powerful tool in the study of drug distribution and metabolism.
Reid DG; Murphy PS
Drug Discov Today; 2008 Jun; 13(11-12):473-80. PubMed ID: 18549972
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy.
Li CW; Negendank WG; Padavic-Shaller KA; O'Dwyer PJ; Murphy-Boesch J; Brown TR
Clin Cancer Res; 1996 Feb; 2(2):339-45. PubMed ID: 9816177
[TBL] [Abstract][Full Text] [Related]
17. [Fluorine-19 nuclear magnetic resonance spectroscopy: a privileged tool for the study of the metabolism and pharmacokinetics of fluoropyrimidines].
Malet-Martino MC; Martino R; Armand JP
Bull Cancer; 1990; 77(12):1223-44. PubMed ID: 2081282
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review.
Daly PF; Cohen JS
Cancer Res; 1989 Feb; 49(4):770-9. PubMed ID: 2643462
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive spectroscopic analysis of fluoropyrimidine metabolism in cultured tumor cells.
Keniry M; Benz C; Shafer RH; James TL
Cancer Res; 1986 Apr; 46(4 Pt 1):1754-8. PubMed ID: 3456267
[TBL] [Abstract][Full Text] [Related]
20. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
